Key takeaways<\/h2>\n\n- \n
Medications that impact the pathways that play a role in the metabolism of Nurtec can be dangerous, resulting in increased or decreased exposure to the active ingredient. <\/span><\/p>\n<\/li>\n- \n
Adverse effects that can result from Nurtec interactions involve the change in exposure to the active ingredient; interactions that increase metabolism can result in individuals not experiencing the therapeutic benefit of the medication, whereas those that decrease metabolism can result in increased exposure and possible <\/span>side effects<\/span>. <\/span><\/p>\n<\/li>\n- \n
While a major substrate of <\/span>CYP3A4<\/span> and P-glycoprotein, Nurtec is a minor substrate of CYP2C9, which may result in less severe impacts on its metabolism when given with other medications that impact that metabolic pathway. <\/span><\/p>\n<\/li>\n- \n
In the event of a Nurtec interaction, if it is identified that the interaction is resulting in increased exposure to the medication, individuals should monitor for new onset of <\/span>side effects<\/span> and hold off on re-dosing Nurtec for a minimum of 48 hours. In the setting of concomitant administration, which results in decreased exposure and potentially a reduction in therapeutic efficacy, individuals should not exceed the recommended dose without the advice of a <\/span>healthcare professional<\/span>.<\/span><\/p>\n<\/li>\n<\/ul>\n<\/div>\n<\/div>\n\n\n\n\n
\n\t\t\t\t\t\t\t\t![](\"https:\/\/www.singlecare.com\/blog\/wp-content\/themes\/singlecare\/images\/union.svg\")
<\/span>
\n\t\t\t\t\t\t\t
Medications that impact the pathways that play a role in the metabolism of Nurtec can be dangerous, resulting in increased or decreased exposure to the active ingredient. <\/span><\/p>\n<\/li>\n Adverse effects that can result from Nurtec interactions involve the change in exposure to the active ingredient; interactions that increase metabolism can result in individuals not experiencing the therapeutic benefit of the medication, whereas those that decrease metabolism can result in increased exposure and possible <\/span>side effects<\/span>. <\/span><\/p>\n<\/li>\n While a major substrate of <\/span>CYP3A4<\/span> and P-glycoprotein, Nurtec is a minor substrate of CYP2C9, which may result in less severe impacts on its metabolism when given with other medications that impact that metabolic pathway. <\/span><\/p>\n<\/li>\n In the event of a Nurtec interaction, if it is identified that the interaction is resulting in increased exposure to the medication, individuals should monitor for new onset of <\/span>side effects<\/span> and hold off on re-dosing Nurtec for a minimum of 48 hours. In the setting of concomitant administration, which results in decreased exposure and potentially a reduction in therapeutic efficacy, individuals should not exceed the recommended dose without the advice of a <\/span>healthcare professional<\/span>.<\/span><\/p>\n<\/li>\n<\/ul>\n<\/div>\n<\/div>\n
\n\t\t\t\t\t\t\t\t<\/span>
\n\t\t\t\t\t\t\t